A biotech is proposing a plan to pay for its pricey rare-disease treatment the same way you’d buy a TV or dishwasher. Here’s the inside story.
|01/10/2019||Posted by BusinessMediaguide.Com under General World News||
- Biotech company Bluebird Bio proposed a five-year installment plan for its pricey gene therapy at a major healthcare conference on Tuesday.
- The company hasn’t put out a price tag for the experimental product, which hasn’t yet been approved, but capped it at $2.1 million a treatment.
- Bluebird CEO Nick Leschly told Business Insider the inside story of how the plan came about and what challenges it could face.
Installment plans are used for big-ticket items like dishwashers and TVs — and now, for medical treatments?
That’s exactly what the biotech Bluebird Bio is suggesting for its cutting-edge, experimental gene therapy, LentiGlobin, which is intended read more >>>